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Follistatin is known to antagonise the function of several members of the TGF-h family of secreted signalling factors, including
Myostatin, the most powerful inhibitor of muscle growth characterised to date. In this study, we compare the expression of Myostatin and
Follistatin during chick development and show that they are expressed in the vicinity or in overlapping domains to suggest possible
interaction during muscle development. We performed yeast and mammalian two-hybrid studies and show that Myostatin and Follistatin
interact directly. We further show that single modules of the Follistatin protein cannot associate with Myostatin suggesting that the entire
protein is required for the interaction. We analysed the interaction kinetics of the two proteins and found that Follistatin binds Myostatin with
a high affinity of 5.84  1010 M. We next tested whether Follistatin suppresses Myostatin activity during muscle development. We
confirmed our previous observation that treatment of chick limb buds with Myostatin results in a severe decrease in the expression of two key
myogenic regulatory genes Pax-3 and MyoD. However, in the presence of Follistatin, the Myostatin-mediated inhibition of Pax-3 and MyoD
expression is blocked. We additionally show that Myostatin inhibits terminal differentiation of muscle cells in high-density cell cultures of
limb mesenchyme (micromass) and that Follistatin rescues muscle differentiation in a concentration-dependent manner. In summary, our data
suggest that Follistatin antagonises Myostatin by direct protein interaction, which prevents Myostatin from executing its inhibitory effect on
muscle development.
D 2004 Elsevier Inc. All rights reserved.Keywords: Follistatin; Myostatin; Myogenesis; Chick; Embryo; Development; Pax-3; MyoD
Introduction respond to Myostatin by down-regulating the expression ofMyostatin, a member of the transforming growth factor-
beta (TGF-h) family of signalling molecules, has been
implicated in determining muscle size by restricting muscle
growth (McPherron and Lee, 1997; McPherron et al., 1997).
During development, Myostatin is expressed at the appro-
priate time and positions to locally decrease the rate of
muscle growth without interfering with the establishment of
the muscle pattern (Amthor et al., 2002b). Myogenic cells0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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1 Contributed equally to this work.key transcriptional regulators of muscle development such
as Pax-3,MyoD andMyf-5, which inhibit differentiation and
further growth of muscle.
Follistatin, a secreted glycoprotein, antagonises numer-
ous members of the TGF-h superfamily including Myo-
statin (Amthor et al., 2002a; Fainsod et al., 1997;
Hemmati-Brivanlou et al., 1994; Iemura et al., 1998;
Michel et al., 1993; Zimmers et al., 2002). Follistatin
and Myostatin are expressed in or near developing muscle
(Amthor et al., 1996, 1999, 2002a,b). However, it has not
yet been demonstrated whether Follistatin and Myostatin
interact directly. Experimentally induced over-expression
of Follistatin results in muscle enlargement, whereas the
Follistatin/ KO mouse displays muscle deficiency (Lee
and McPherron, 2001; Matzuk et al., 1995). In the
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and Myostatin-induced muscle loss can be prevented (Lee
and McPherron, 2001; Zimmers et al., 2002). Although both
Myostatin and Follistatin are detected in serum, they do not
associate in this medium. Instead, Myostatin circulates as a
complex by associating either with the Myostatin propeptide,
with FLRP, a Follistatin-related protein, or with GASP, which
is a putative protease inhibitor that contains a Follistatin-like
domain (Hill et al., 2002, 2003). This raises the question
whether Follistatin andMyostatin interact directly or whether
both proteins use independent signalling cascades.
The Follistatin gene undergoes alternative splicing to
yield either short or long forms of mRNAs. These are
translated into pre-proteins and then modified to remove
the signal sequence (reviewed by Patel, 1998). The short
isoform yields a protein composed of 288 amino acids (FS-
288), which is 8–10 times more biologically active than the
product of the long isoform (FS-315) (Inouye et al., 1991).
Myostatin is synthesised as a precursor protein, which
consists of a N-terminal propeptide domain that harbours the
signal sequence and a C-terminal domain that forms a
disulfide-linked dimer and functions as the active ligand
(McPherron et al., 1997; Thomas et al., 2000). After cleav-
age of the propeptide, a large fraction of Myostatin is still
non-covalently bound to its propeptide and requires release
from the propeptide to attain biological activity (Lee and
McPherron, 2001; Zimmers et al., 2002). Myostatin binds
the Activin Receptor Type IIB, which leads to the intracel-
lular phosphorylation of Smad3 (Langley et al., 2002; Lee
and McPherron, 2001; Massague and Chen, 2000; McPher-
ron and Lee, 1996). Phosphorylated Smad3 can bind other
Smad proteins and these complexes translocate into the
nucleus, where they regulate the transcription of target genes
(Massague and Chen, 2000). Additionally, phosphorylated
Smad3 binds and thereby inhibits the transcriptional activity
of MyoD (Liu et al., 2001).
In the first part of this study, we have compared the
expression pattern of Myostatin and Follistatin with a view
to detect evidence that these proteins may interact during
muscle development. We next determined whether Follista-
tin binds Myostatin using yeast and mammalian two-hybrid
systems. We analysed the kinetics of the Myostatin–Folli-
statin interaction using surface plasmon resonance. We have
subsequently tested the biological relevance of this interac-
tion by applying recombinant Myostatin and Follistatin to
developing muscle of chick embryonic limb buds both in
vitro and in vivo.Materials and methods
Yeast two-hybrid studies
The DupLEX-Ak yeast two-hybrid system (Origene)
was used to test protein–protein interactions. The C-
terminal coding region of mouse Myostatin (bp 905–1234; Genbank accession number, NM010834) encoding
the processed or mature portion of Myostatin was cloned
into the pEG202 bait plasmid (carrying the HIS3 gene)
containing the Lex-A DNA binding domain using BamH1
restriction sites (LexA-MSTNmat). The portion of mouse
Follistatin (bp 88–948; Genbank accession number,
NM08046) encoding the Follistatin was cloned into the
pJG4-5 target plasmid (carrying the TRP1 gene) containing
the B42 DNA activation domain using EcoR1 restriction
sites (B42-FS-288). This portion of mouse Follistatin (1–
287) is analogous to the active human Follistatin-288 and
therefore is referred to in this manuscript as Follistatin-
288. Interaction between the encoded fusion proteins was
investigated by co-transforming the bait and target plas-
mids together with the reporter gene (lacZ) plasmid
pJK103 (carrying the URA3 gene) into the yeast strain
EGY194 (MATa trp1 his3 ura3 leu2:4 LexAop-LEU2).
Transformed yeast cells were plated onto medium lacking
histidine, uracil and tryptophan and grown at 30jC for 3
days to select for the presence of the three plasmids. Two
independent colonies were then transferred to medium
lacking histidine, uracil, tryptophan and leucine for 3 days
at 30jC to select for positive interactions between mature
Myostatin and Follistatin-288. Positives clones were then
tested for expression of the second reporter gene, lacZ, by
growth on medium containing X-gal and lacking histidine,
uracil and tryptophan. In the DupLEXk system, expres-
sion of the target-B42 activation domain fusion protein is
galactose-inducible and therefore galactose growth-depen-
dence was also tested. Finally, positives clones were tested
against the negative bait control pEG202max to ensure
specificity.
To map the binding site of Follistatin to mature Myo-
statin, cDNA encoding truncations of Follistatin 1–63, 64–
288, 1–86, 1–100, 1–136, 1–150, 1–200 and 1–250 were
cloned into pJG4-5 to create target plasmids, which were
tested against the mature Myostatin bait plasmid as de-
scribed above.
Mammalian two-hybrid studies
The TOPOR Tools Mammalian Two Hybrid Kit (Invi-
trogen) was used to verify yeast two-hybrid results. The C-
terminal coding region of Myostatin (bp 905–1234; Gen-
bank accession number as above) encoding the processed
portion of Myostatin was TOPOR joined to the Psv40-
GAL4 5V element and SV40 pA 3V element according to the
manufacturer’s instructions to create a linear DNA template
for the bait protein (GAL4-MSTNmat). Similarly, the por-
tion of Follistatin (bp 88–948; Genbank accession number
as above) encoding the active Follistatin was TOPOR joined
to the Psv40-VP16 5V element and SV40 pA 3V element to
create a linear DNA template for the prey protein (VP16-FS-
288). The linear DNA templates were PCR amplified using
a proofreading polymerase and the following primers: 5V-
TATGTATCATACACATACGATTTAGGT-3V and 5V-
H. Amthor et al. / Developmental Biology 270 (2004) 19–30 21GACTCAAAGGGAACTTGTTTATTGCAGCTTA-
TAATG-3V and PCR products were purified.
CHO cells (American Tissue Culture Collection), a
Chinese hamster ovary cell line, were maintained in Dul-
becco’s modified Eagle medium (DMEM)/F12 (1:1) (Invi-
trogen) containing 10% fetal bovine serum (Sigma), 1  105
IU/l penicillin (Sigma) 100 mg/l streptomycin (Sigma) and
27.8 mM NaHCO3 (maintenance medium) at 37jC in a
humidified atmosphere of 5% CO2.
Thirty nanograms of the bait and prey linear constructs
were co-transfected along with the reporter plasmid
pGAL/lacZ into CHO cells seeded at 2  104 cells per
well on a 96-well plate using Lipofectamine 2000 (Invi-
trogen) according to the manufacturer’s instructions. After
24 h, the medium was changed to fresh maintenance
medium. After a further 24 h, cells were fixed for in situ
staining of h-galactosidase activity by hydrolysis of X-gal.
For in situ staining, media was discarded from wells and
the cells fixed with 0.05% glutaraldehyde for 15 min at
room temperature. Cells were rinsed thoroughly with three
washes of PBS and incubated for 1 h at 37jC with 1 mg/
ml X-gal in 35 mM K3Fe(CN)6, 35 mM K4Fe(CN)63H20
and 2 mM MgCl2.
Control transfections were carried out to ensure specific-
ity of interactions. For the background control, no DNAwas
transfected. Mature Myostatin and active Follistatin were
also tested against the pCR2.1/LgT prey control plasmid
and pCR2.1/p53 bait control plasmid, respectively, proteins
with which they should not interact.
Surface plasmon resonance
All plasmon surface resonance experiments were per-
formed using the BIACORE 3000. Purified recombinant
human Follistatin and recombinant mouse Myostatin were
purchased from R&D System (USA). Follistatin was
immobilised onto the surface of a CM5 sensor chip
(600 resonance units) using amine-coupling chemistry. A
range of Myostatin concentrations were injected over the
sensor chip surface at a flow rate of 30 Al/min at 25jC.
Hepes-buffered saline (HBS: 10 mM Hepes, 150 mM
NaCl, 3.4 mM EDTA, 0.005% Tween 20 pH 7.4) was
used as a running buffer and for sample dilution. For
controls, Myostatin was run over a derivatised sensor
chip, which lacked Follistatin. All Myostatin curves were
corrected by subtraction of the blank run. Biacore evalu-
ation software was used for the mathematical fitting of
experimental data.
Preparation of chick embryos
Fertilised chick eggs were incubated at 38jC, and the
embryos were staged according to Hamburger and Hamilton
(1992). Experiments were performed on embryos at stages
22 to 24, re-incubated between 6 and 8 h, sacrificed and
processed for whole-mount in situ hybridisation.Myostatin and Follistatin bead preparation and application
to limb buds
Recombinant Myostatin and Follistatin protein were
purchased from R&D Systems. Myostatin was applied to
80- to 120-Am Affigel beads and Follistatin to Heparin
beads of same size (both Sigma, UK). The proteins were
loaded onto beads as described by Cohn et al. (1995).
Myostatin and Follistatin were used at 1 mg/ml concentra-
tion. For control bead implantation, beads were soaked in
PBS only. For bead implantation, the dorsal ectoderm and
mesenchyme of the right wing were punctured with an
electrolytically sharpened tungsten needle, and beads were
inserted into the punctured mesenchyme using a blunt glass
needle. Beads were implanted at HH-stages stated in the
text.
Whole-mount in situ hybridisation
All chick embryos were washed in PBS and then fixed
overnight in 4% paraformaldehyde at 4jC. Anti-sense RNA
probes were labelled with digoxygenin, and whole-mount in
situ hybridisation was performed as described by Nieto et al.
(1996). The following probes were used in this study:
Follistatin, full-length fragment, 1.1 kb (gift from Dr.
Anthony Graham); Myostatin, 1 kb fragment (gift from
Professor Se Jin Lee); MyoD, clone CMD9 full 1.5 kb
length fragment (gift from Professor Bruce Patterson) and
Pax-3, 645 bp fragment corresponding to nucleotides 468–
1113 (gift from Dr Martin Goulding). Whole-mount embry-
os were wax or cryo-sectioned at a thickness of 15 Am for
histological examination.
Chick limb bud micromass assay
Micromass assays were carried out as described in
Swalla and Solursh (1986). Briefly, limb buds from HH
stages 21–22 chick embryos were dissected and placed into
a 0.05% Trypsin-EDTA solution (Invitrogen). The ectoderm
was removed using tungsten needles and a single cell
suspension of the limb bud mesenchyme was obtained.
Micromass cultures were plated at 2  105 cells in 10
Al drops, allowed to adhere for 2 h and then treated with
media (DMEM, 10% Fetal Calf Serum—Invitrogen) con-
taining either Myostatin or Myostatin plus Follistatin at
concentrations stated in the text (R&D Systems). Micromass
cultures were then fixed in 4% PFA and processed for
myosin heavy chain (MHC) immunocytochemistry. Cul-
tures were dehydrated through a methanol series and treated
with hydrogen peroxide to eliminate endogenous peroxidase
activity. After rehydration, cultures were incubated with a
monoclonal anti-PanMHC antibody (clone A41025, gift
from Dr Simon Hughes) in the presence of 10% horse
serum. After washing in PBS, rabbit anti-mouse biotin
secondary antibody (Dako) was applied, cultures again
washed, then incubated with an avidin–biotin complex
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DAB/hydrogen peroxide reaction (Vector Laboratories)
according to manufacturer’s protocols.Results
Co-expression of Follistatin and Myostatin related to
muscle development
We have previously published independent detailed ex-
pression patterns of Follistatin and Myostatin during chick
embryonic development (Amthor et al., 1996, 1999,
2002a,b), which suggested an overlap in expression at sites
of muscle development. Here, we directly compared the
expression pattern of both genes during limb and trunk
muscle development.
Abutting or overlapping expression of Follistatin and
Myostatin during wing bud development occurs for the
first time at HH-stages 25–26. Follistatin is highly
expressed in the proximal wing bud and fades distally
(Fig. 1A). Myostatin is expressed in a central domain and
the expression extends more distally compared to Folli-
statin (Fig. 1B). Transverse sections through the proximal
part of the wing buds reveal expression of Follistatin in
the subectodermal mesenchyme and in a central domain of
the dorsal premuscle mass (Fig. 1E). Myostatin is
expressed in the mesenchymal core of the limb bud and
also in a central domain of dorsal premuscle mass (Fig.
1F). However, at this stage, the expression of Follistatin
and Myostatin does not encompass the entire premuscle
mass as indicated by the expression of Pax-3 and MyoD
(Figs. 1C and D). Follistatin expression is increased in the
muscle masses up to HH-stage 31, whereas during these
stages, Myostatin expression is only found in some sub-
domains of the developing muscle (Figs. 1G and H).
Thereafter, at late embryonic stages, Follistatin is down-
regulated in muscle, but expression resides in the connec-Fig. 1. Follistatin and Myostatin are expressed in or close to developing muscle.
wing and interlimb somite development. (A–D) HH-stage 26 wing buds, dorsal v
somites, lateral view and (M–P) corresponding frontal sections. (Q–T) Transverse
expression, which fades distally in stage 26 wing bud. Section level indicated with
wing bud in contrast to the broader extension of the Pax-3-expressing (C) and M
shows Follistatin expression in a distinct location of the dorsal premuscle mass (
section of (B) shows Myostatin expression in a distinct location of the dorsal pre
Follistatin and Myostatin expression in dorsal and ventral zeugopod muscles (arr
expression in distinct muscle subdomains (compare G and H, arrows). (I) Strong
domain in contrast to the high Myostatin expression in the somite centre (J). So
domain, moderate expression in the cranial and caudal domain of the dermomyot
highlights the full extent of the myotome. (M) Frontal section shows high Follistat
expression in the myotome. Brackets mark extent of somites. (N) Myostatin expres
caudal dermomyotomal edges nor in the dorsomedial and ventrolateral edges
dermomyotome (arrowheads). Intermediate expression in the dermomyotomal cen
marks the cranio-caudal extent of the myotome. (Q) Transverse section reveals h
expression in the myotome. (R) Myostatin expression in the central part of the d
hypaxial, moderate in the intermediate and no expression in the dorsomedial dom
expression marks the full extent of the myotome.tive tissue surrounding the muscles, whereas Myostatin is
increasingly expressed in most of the muscles (data not
shown, see also Amthor et al., 2002b).
Although Follistatin is expressed in interlimb somites as
soon as they are formed, Myostatin is not up-regulated
before HH-stage 19 (Amthor et al., 2002b). In stage 21
interlimb somites, Follistatin is strongly expressed at the
cranial and caudal edges of the dermomyotome and in the
hypaxial somite domain, whereas there is only a faint
expression in the somite centre (Figs. 1I, M, Q). The
expression of Myostatin is almost complementary to that
of Follistatin as it is expressed in a central domain of the
dermomyotome, but not at the somite edges or in the
hypaxial domain (Figs. 1J, N, R). Highest expression level
of Follistatin coincides with a high expression level of Pax-
3 (Figs. 1K, O, S) but not of MyoD (Figs. 1L, P, T). At later
stages, both Follistatin and Myostatin are predominantly
expressed in hypaxial muscle (data not shown, see also
Amthor et al., 2002b).
These data show that Follistatin and Myostatin are
expressed in or close to developing muscle. They are
expressed partly in overlapping domains and partly in
abutting regions to each other. As both Myostatin and
Follistatin are secreted signalling proteins, they appear to
be expressed sufficiently close to enable protein–protein
interaction.
Two-hybrid investigations of Follistatin–Myostatin
interaction
Overexpression of Follistatin in mouse skeletal muscle
results in a double-muscle phenotype that is similar to
Myostatin knockout mice (Lee and McPherron, 2001).
Follistatin has also been shown to inhibit Myostatin activity
in a transcription-based reporter assay (Zimmers et al.,
2002). Furthermore, systemic administration of Follistatin
was shown to interfere with the activity of Myostatin
produced at distant sites in vivo (Zimmers et al., 2002).Comparison of Follistatin, Myostatin, Pax-3 and MyoD expression during
iew. (E–H) Transverse sections of wing buds. (I –L) HH-stage 21 interlimb
sections of HH-stage 21 interlimb somites. (A) Strong proximal Follistatin
broken green line. (B)Myostatin expression in a central domain of a stage 26
yoD-expressing (D) dorsal premuscle mass. (E) Transverse section of (A)
arrow) and in the subectodermal mesenchyme (arrowhead). (F) Transverse
muscle mass (arrow) and in the mesenchymal core (arrowhead). (G and H)
ows) at HH-stage 30. Follistatin expression partly overlaps with Myostatin
Follistatin expression at cranial and caudal somite edges and in a hypaxial
mite demarked by dotted line. (K) High Pax-3 expression in the hypaxial
ome (see also O) and no expression dorsomedially (see also S). (L) MyoD
in expression in the cranial and caudal somite edges (arrowheads) and weak
sion in the dermomyotomal and myotomal centre, but not at the cranial and
(R). (O) High Pax-3 expression in the cranial and caudal part of the
tre (arrow) and in the dorsal root ganglia (asterisks). (P) MyoD expression
igh Follistatin expression in the hypaxial domain of the somite with weak
ermomyotome and myotome. (S) Highest level of Pax-3 expression in the
ain of the dermomyotome. Asterisk marks dorsal root ganglion. (T) MyoD
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Myostatin, rather than acting indirectly, and to identify the
putative binding site of Follistatin. We used the yeast two-
hybrid system to test for interaction between mature Myo-
statin and Follistatin-288 and then confirmed interactions
using a mammalian two-hybrid system. Follistatin-288, was
expressed as a target fusion protein to the B42 DNA
activation domain (B42-FS-288). The fusion protein was
tested for interaction in the yeast two-hybrid system with the
mature portion of Myostatin expressed as a bait fusion
protein to the LexA DNA binding domain (LexA-
MSTNmat). Transactivation of the lacZ reporter occurred
in yeast co-transformed with LexA-MSTNmat and B42-FS-
288 only in the presence of galactose but not on medium
containing glucose, consistent with the galactose dependen-
cy of the GAL1 promoter used to drive expression of the
B42-FS-288 fusion protein (Fig. 2). Similarly, transactiva-
tion of LEU2 in yeast co-transformed with LexA-mature-
Myostatin and B42-FS-288 expression plasmids grown on
medium lacking leucine occurred only in the presence of
galactose.
To determine which regions of Follistatin may be impor-
tant for physical and functional interactions with mature
Myostatin, we generated a series of Follistatin truncations as
fusion proteins to the B42 activation domain. Initially,
Follistatin-288 was divided into the N-terminal domain (aa
1–63) and the region composed of the three ‘‘Follistatin
domains’’ (aa 64–288). Distinct and non-overlapping pro-
tein binding sites of Follistatin have previously beenFig. 2. Mature Myostatin interacts specifically with Follistatin-288. Lex A-Myost
two-hybrid assays were performed with lacZ reporter gene and the LEU2 selection
(FS-288) transactivated the lacZ locus as visualised by X-gal staining. B42 wa
containing galactose, but not glucose, resulted in transactivation of lacZ in the p
MSTNmat was not able to autoactivate lacZ. Likewise transactivation of LEU2, w
in the presence of mature Myostatin and Follistatin-288. Again, Lex A was not ab
glucose. We also tested the ability of mature Myostatin to interact with various Fo
1–150, 1–200 and 1–250) as well as the control vector pEG202-Max to interacreported in these regions. A heparin sulphate-binding region
is located within the first Follistatin domain: aa 75–86
(Inouye et al., 1992; Sumitomo et al., 1995). Two discon-
tinuous sequences capable of binding Activin have also
been identified within the 63-residue N-terminal domain: aa
3–26 and aa 46–59 (Wang et al., 2000). Neither of these
domains interacted with mature Myostatin in the yeast two-
hybrid system. Further Follistatin truncations, Follistatin 1–
86, 1–100, 1–136, 1–150, 1–200 and 1–250, also failed to
interact with mature Myostatin in the yeast two-hybrid
system (Fig. 2).
These results show that the N-terminal domain and the
three Follistatin modules on their own are not sufficient to
interact with Myostatin and suggest that these domains
together constitute essential Myostatin-binding determi-
nants. The interaction may either be mediated through
several epitopes of the tertiary structure of Follistatin or
deletion of any part of Follistatin may profoundly alter the
conformation and thus prevent binding.
After establishing a specific interaction between Folli-
statin-288 and mature Myostatin, we wanted to corroborate
the result in mammalian cells. Mammalian proteins are more
likely to retain their native confirmation in a mammalian
cell. Bait and prey fusion constructs consisting of mature
Myostatin and Follistatin-288, respectively, were co-trans-
fected with the lacZ reporter plasmid into CHO cells.
Identical results were obtained in the mammalian two-
hybrid system as in the yeast two-hybrid system. Mature
Myostatin and Follistatin-288 specifically interacted inatin and B42-Follistatin fusion proteins were expressed in yeast, and yeast
marker. Only expression of both mature Myostatin and full-length Follistatin
s under the control of a galactose-dependent promotor and only medium
resence of mature Myostatin and Follistatin-288, which shows that Lex A-
hich enabled growth of yeast cells in absence of leucine, was only achieved
le to autoactivate lacZ as cells grew only in presence of galactose, but not
llistatin domains (encoded by amino acids 1–63, 64–288, 1–100, 1–136,
t with Follistatin-288, but all gave negative results.
Fig. 3. Mature Myostatin and Follistatin-288 interact in mammalian cells. The positive interaction between mature Myostatin and Follistatin-288 was confirmed
in the mammalian two-hybrid system. Mature Myostatin as a fusion to GAL4 DNA binding domain and Follistatin-288 as a fusion to the VP16 activation
domain together with a reporter plasmid containing the lacZ gene were co-transfected into CHO cells, which were then assayed for h-galactosidase activity.
CHO cells were fixed and stained in situ with X-gal. (A) Positive X-gal staining was seen in cells transfected with GAL4-MSTNmat, VP16-FS-288 and pGAL/
lacZ, which indicates an interaction between Myostatin and Follistatin, but not in cells lacking either (B) Follistatin: GAL4-MSTNmat, pCR2.1/LgT prey
control and pGAL/lacZ or (C) Myostatin: VP16-FS-288, pCR2.1p53 bait control and pGAL/lacZ. Magnification: 200.
H. Amthor et al. / Developmental Biology 270 (2004) 19–30 25CHO cells to induce expression of the reporter gene lacZ as
observed by in situ staining for h-galactosidase (Fig. 3).
Mature Myostatin and Follistatin-288 did not, however,
interact with control plasmids, verifying the specificity of
the interaction.
Follistatin–Myostatin interaction kinetics
Our studies using yeast and mammalian two-hybrid
systems clearly show that Follistatin is able to interact with
Myostatin. To determine the kinetics of this interaction, we
employed a Surface Plasmon Resonance Biosensor (Bia-
core), which allows the affinity between two associating
molecules to be determined. In a first step, Follistatin was
irreversibly bound onto the surface of a dextran-coated
sensory chip and subsequently exposed to differing concen-
trations of Myostatin. The interaction analysis consisted of
two parts. In the first part of the measurement, Follistatin
was exposed to its ligand Myostatin, which allowed protein
complexes to be formed. In the second part, Myostatin was
no longer present and the Follistatin coated sensor chip
surface was washed to allow the dissociation of the proteinFig. 4. Surface plasmon resonance investigations of the Follistatin–Myostatin inte
increasing resonance units (RU) as the Follistatin coupled sensor chip was exposed
of dissociation of Follistatin is shown by the decrease in RU units for the different
chip to Hepes-buffered saline for approximately 480 s.complexes. The Follistatin–Myostatin interaction was mea-
sured in response units from which association and disso-
ciation constants were calculated using the Biacore
evaluation software.
Follistatin–Myostatin interactions were studied at 6.25,
12.5, 25, 50 and 100 nM, and a reproducible series of
concentration-dependent interaction curves were generated
(Fig. 4). The gentle increase in the curves during the binding
phase suggested a low association rate. More importantly,
however, during the dissociation phase, the curves did not
descend appreciably, which suggests that the Follistatin–
Myostatin complex was very stable. The experimental data
were fitted to the Langmuir (1:1) model of interaction, which
resulted in an average association constant of (ka) 1.63 105
M1 s1 and a dissociation constant of (kd) 9.52  105 s1.
From these values, the affinity (kD) of Follistatin for Myo-
statin was calculated to be 5.84  1010 M.
These results provide an independent additional means to
show that Follistatin directly interacts with Myostatin. The
kinetics of the interaction demonstrates that once Myostatin
had bound Follistatin it did not readily dissociate from this
coupling.raction. Association of Follistatin–Myostatin complexes was measured by
to different concentrations of Myostatin for approximately 175 s. The level
Myostatin concentrations after the exposure of the Follistatin-coupled sensor
H. Amthor et al. / Developmental Biology 270 (2004) 19–3026Follistatin prevents the Myostatin-mediated inhibition of
embryonic limb muscle development
We recently reported that Myostatin retarded growth of
limb muscle when applied to the developing wing bud of
chick embryos (Amthor et al., 2002b). We showed that the
inhibiting effect of Myostatin on muscle development was
mediated by the down-regulation of Pax-3 and MyoD
expression, and we found that the gene expression is altered
within 6 h after exposure to Myostatin. Here, we tested
whether the presence of Follistatin can prevent the effect of
Myostatin on Pax-3 and MyoD expression. We used Affigel
Blue beads and Heparin beads as protein carriers for
Myostatin and Follistatin, respectively, and used the same
proteins as for the Biacore kinetic evaluation. In previousFig. 5. Follistatin antagonises Myostatin to block myogenesis during limb develop
transverse section at mid-limb level after Follistatin and Myostatin bead implantati
beads in wing buds. Columns A, F, K, P, U show MyoD expression in wing whol
mounts. Columns C, H, M, R, W show Pax-3 expression in wing whole-mounts
Asterisks show beads. (A, B) Normal MyoD expression in dorsal and ventral p
expression in dorsal and ventral premuscle masses in a non-manipulated wing bud
expression in dorsal and ventral premuscle masses after control bead implantation.
control bead implantation. (J) Arrangement for Follistatin bead implantation (K–N
after Follistatin bead application is not visible in whole-mount, but after sectioning
after Follistatin bead implantation. (O) Arrangement for Myostatin bead implanta
moderate down-regulation in the ventral premuscle mass after Myostatin bead
premuscle mass after Myostatin bead implantation. (T) Arrangement for concu
complete rescue of MyoD expression in dorsal and complete rescue in ventral prem
(W, X) Complete rescue of Pax-3 expression in dorsal and ventral premuscle mastudies, we found that experiments were most effective and
reproducible when multiple beads were implanted (Amthor
et al., 2002a). We, therefore, applied 8 to 11 Myostatin
beads and additionally 8 to 11 Follistatin beads to HH-
stages 22–24 wing buds, and in control experiments, the
same number of beads soaked in PBS. Previously, we found
that control beads never altered any gene expression, tissue
architecture nor resulted in induced cell death (Amthor et
al., 1998). Nevertheless, we performed a control experiment
and tested the effect of Affigel Blue beads and Heparin
beads, which had been soaked in PBS only, on the expres-
sion of Pax-3 and MyoD. At least eight Affigel Blue beads
and at least eight Heparin beads were microsurgically placed
into the dorsal subectodermal mesenchyme of HH-stages
22–24 wing buds and embryos were re-incubated for ament. Dorsal view on HH-stage 24/25 chick wing buds and corresponding
on and a 6-h re-incubation period. Columns E, J, O, T show arrangement of
e-mounts. Columns B, G, L, Q, V show transverse section of MyoD whole-
. Columns D, I, N, S, X show transverse section of Pax-3 whole-mounts.
remuscle masses in a non-manipulated wing bud. (C, D) Normal Pax-3
. (E) Bead arrangement for control experiment (F–I). (F, G) Normal MyoD
(H, I) Normal Pax-3 expression in dorsal and ventral premuscle masses after
). (K, L) Slight decrease in MyoD expression in the dorsal premuscle mass
. (M, N) Normal expression of Pax-3 in dorsal and ventral premuscle masses
tion (P–S). (P, Q) Almost total loss of MyoD expression in the dorsal and
implantation. (R, S) Almost total loss of Pax-3 expression in the dorsal
rrent Follistatin and Myostatin bead implantation (U–X). (U, V) Almost
uscle masses after concurrent Follistatin and Myostatin bead implantation.
sses after concurrent Follistatin and Myostatin bead implantation.
Fig. 6. Follistatin antagonises the ability of Myostatin to block terminal
differentiation of muscle in micromass cultures. Differentiated muscle is
shown by expression of Myosin heavy chain (MHC) after immunohisto-
chemistry. Chick limb bud mesenchyme was cultured as micromasses.
Cultures were untreated (A), supplemented with 125 ng/ml Myostatin (B),
125 ng/ml Myostatin plus 156 ng/ml Follistatin (C), 125 ng/ml Myostatin
plus 312 ng/ml Follistatin (D) or 125 ng/ml Myostatin plus 625 ng/ml
Follistatin (E). Myostatin alone significantly reduced the number of MHC-
positive cells compared to controls (B compare with A). This effect was
reversed by concurrent addition of Follistatin, in a concentration-dependent
manner (C–E).
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Heparin beads (white colour) were alternately arranged
(Fig. 5E). In each case, all beads were still well positioned
and evenly spaced at the time of fixation. Wing buds neither
changed in size nor in shape despite the high number of
control beads. Furthermore, we found no alteration in the
intensity or in the extent of Pax-3 orMyoD expression in the
dorsal and ventral premuscle masses compared to unoper-
ated wings (Pax-3, n = 11; MyoD, n = 7) (Figs. 5A–I). After
transverse sectioning of such wing buds, we found that the
control beads did not alter the tissue architecture or the
expression of Pax-3 and MyoD when compared to unoper-
ated wings.
We previously found that Follistatin moderately in-
creased the expression of Pax-3 and decreased the
expression of MyoD (Amthor et al., 2002a). However,
we had not examined the short-term effect of Follistatin
as early as 6 h after protein application. Here, we placed
8–11 Heparin beads soaked in Follistatin and additionally
8–11 Affigel Blue beads soaked in PBS (which in
subsequent experiments have been replaced with Myo-
statin beads) in the developing wing buds (Fig. 5J). Six
to 7 h after such operation, we found no obvious
alteration of Pax-3 expression compared to control bead
implantation (n = 7) (Figs. 5M–N and compare to Figs.
5H–I). When the effect of Follistatin on MyoD expres-
sion was examined, we observed in approximately 50%
of cases a faint decrease in MyoD expression compared
to the effect of control beads (n = 9) (Figs. 5K–L and
compare to Figs. 5F–G).
To test for the effect of Myostatin on the expression of
Pax-3 and MyoD, we placed 8–11 Affigel Blue beads
soaked in Myostatin and additionally 8–11 Heparin beads
soaked in PBS (which in the subsequent experiments have
been replaced with Follistatin beads) in the developing
wing buds (Fig. 5O). Six to 8 h after Myostatin exposure,
we found a drastic down-regulation of Pax-3 as well as
MyoD expression in the dorsal and to a lesser extent in the
ventral premuscle masses compared to control experiments
(Pax-3, n = 12; MyoD, n = 8). We occasionally found
operated wings with residual Pax-3 and MyoD expression,
which was in the centre of the dorsal side of the wing
buds, whereas others lacked Pax-3 and MyoD expression
completely (Figs. 5P–S).
Finally, we tested whether Follistatin, when simulta-
neously applied with Myostatin, can inhibit the effect of
Myostatin. We placed 8–11 Affigel Blue beads soaked in
Myostatin and immediately afterwards an additional 8–11
Heparin beads soaked in Follistatin in the developing wing
buds (Fig. 5T). In all cases, the Pax-3 expression in the
dorsal premuscle masses was rescued in three out of eight
cases completely. Pax-3 expression in the ventral premuscle
masses was completely rescued in all cases (n = 8) (Figs.
5W–X). In cases of incomplete rescue, Pax-3 expression
was observed immediately adjacent to or between the Fol-
listatin beads, whereas the expression was not found near theMyostatin beads. Examination of MyoD expression after
combined Myostatin/Follistatin treatment revealed in two
out of eight cases a nearly complete rescue of MyoD
expression in the dorsal premuscle masses (Figs. 5U–V).
Ventral premuscle masses showed a complete rescue of
MyoD expression in six of eight cases. In cases of incomplete
rescue, MyoD expression was near the Follistatin beads, but
not near the Myostatin beads.
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Myostatin to down-regulate key transcription factors of
muscle development. The antagonising effect of Follistatin
appears to be concentration-dependent because the rescue of
Pax-3 and MyoD expression was highest next to the source
of Follistatin and lowest next to the source of Myostatin.
Chick limb bud cultures confirm the inhibitory effect of
Follistatin on Myostatin
To determine whether Follistatin can block the inhibitory
effect of Myostatin on terminally differentiated muscle, we
tested the effect of both proteins on micromass cultures of
dissociated chick limb bud mesenchyme cells. In these
cultures, limb bud cells differentiate into muscle and carti-
lage when plated at high density (Swalla and Solursh,
1986).
Control micromass cultures (non-Myostatin treated) form
terminally differentiated muscle cells, which are immuno-
reactive against Myosin Heavy Chain (MHC), after a 24-
h culture period (Fig. 6A, n = 10). Supplementing the
micromass cultures with 125 ng/ml Myostatin resulted in
an almost complete lack of MHC-positive cells in all cases
(Fig. 6B, n = 10). Concurrent exposure of micromass
cultures to 125 ng/ml Myostatin and Follistatin at concen-
trations of 156, 312 and 625 ng/ml rescued the formation of
MHC-positive cells (for each concentration, n = 4, Figs. 6C,
D, E). The concurrent addition of Follistatin with Myostatin,
however, rescued this effect in a concentration-dependent
manner, as increased concentrations of Follistatin led to an
increased formation of MHC-positive cells in 100% of
cases. Supplementing with Follistatin alone at concentra-
tions of 156, 312 and 625 ng/ml moderately decreased the
formation of MHC-positive cells (data not shown; for each
concentration, n = 4).
These data show that Follistatin blocked the inhibitory
effect of Myostatin on the formation of differentiated muscle
in a concentration-dependent manner.Discussion
Myostatin is the most powerful inhibitor of muscle
growth identified to date (Kambadur et al., 1997; McPher-
ron and Lee, 1997; McPherron et al., 1997). Our data
suggest that Follistatin antagonises the ability of Myostatin
to inhibit muscle development. This suggestion is based on
following observations: we have shown that Follistatin and
Myostatin are expressed in or very close to developing
muscle. They are expressed in overlapping or in very
closely located domains, which suggests that they can
interact as they both are secreted signalling molecules.
Our in vitro experiments show that the proteins can interact
directly with high affinity. We finally have shown that
Follistatin prevents the inhibiting effect of Myostatin on
muscle development both in vivo and in vitro.The hypertrophy and hyperplasia of muscle, found in the
absence of Myostatin, clearly demonstrates that excessive
muscle growth can be a default pathway (Kambadur et al.,
1997; McPherron and Lee, 1997; McPherron et al., 1997).
We suggest that the implementation of Myostatin during
evolution created a simple mechanism to regulate muscle
growth whenever required by simply up- or down-regulat-
ing Myostatin gene expression or by blocking the Myostatin
protein. The developmental need to accurately tune the
effect of Myostatin is nicely demonstrated during somite
development. From HH-stage 20 onwards, the expression of
Myostatin in the centre of the dermomyotome and myotome
is framed by the expression of Follistatin in the lips of the
dermomyotome. The highest expression of Pax-3 and,
significantly, the generation of muscle cells are found in
the dermomyotomal lips but not in the dermomyotomal
centre (Kahane et al., 1998, 2001). This distribution of
Myostatin and Follistatin expression therefore follows their
predicted functions as observed in the knockout animals: the
Myostatin/ mouse results in excessive muscle growth,
whereas the Follistatin/ mouse displays muscle hypo-
trophy (Matzuk et al., 1995; McPherron et al., 1997).
Myostatin executes its effect via down-regulating the ex-
pression of key transcription factors that control muscle
development, which inhibited further muscle growth
(Amthor et al., 2002b). We demonstrated the rapidity of
Myostatin to inhibit the expression of MyoD and Pax-3
within a matter of a few hours. We show here that Follistatin
can almost completely prevent the effect of Myostatin on
Pax-3 and MyoD expression. Furthermore, we also show
that the ability of Myostatin to inhibit terminal muscle
differentiation is blocked by Follistatin in a concentration-
dependent manner.
One question, which needed to be answered, was whether
Follistatin acts directly or indirectly to antagonise Myostatin.
Firstly, we established that Follistatin interacts with Myo-
statin directly by using three different methods: the yeast
two-hybrid system, the mammalian two-hybrid system and
the surface plasmon resonance biosensor. It may be signif-
icant that interactions between Myostatin and Follistatin
were detected using both yeast and mammalian two-hybrid
systems. This suggests that the post-translational modifica-
tions found solely in higher organism are not required in
order for these two proteins to interact. Next, we attempted to
establish which of the domains of Follistatin were essential
or sufficient for binding to Myostatin. Follistatin consists of
four domains, which have been previously shown to harbour
specific protein binding sites, such as for Heparin and
Activin (Inouye et al., 1992; Sidis et al., 2001; Sumitomo
et al., 1995; Wang et al., 2000). We generated different
Follistatin truncations, but none of the tested Follistatin
domains was able to bind Myostatin on their own. This
suggests that all Follistatin domains together are important
for effective Myostatin binding. However, our experiments
did not determine whether internal deletions of the Follistatin
protein could maintain its ability to bind Myostatin. We
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of Follistatin to bind Myostatin of 5.84  1010 M. The
affinity of Activin to bind the Activin Type II receptor was
estimated to range between 2 and 7  109 M, which
demonstrates that Follistatin is likely to compete with the
binding of Myostatin to its receptor (Donaldson et al., 1999).
Although Follistatin associates with Myostatin at a low rate
compared to the association constant of the Follistatin-BMP
interaction (1.63  105 M1 s1 for Follistatin–Myostatin
compared to 2.06  106 M1 s1 for Follistatin-BMP-7,
(Amthor et al., 2002a; Iemura et al., 1998), the dissociation
constant suggests that once the Follistatin–Myostatin com-
plex has formed, they do not readily dissociate. This results
in the strong affinity of Follistatin for Myostatin. From a
pharmacological perspective, these data predict that the
efficiency of Follistatin to antagonise Myostatin could still
be drastically enhanced if its structure would be altered to
enable a more rapid association.
Follistatin is expressed as soon as somites are formed,
whereas Myostatin expression in trunk somites is not
found before HH-stage 20 (Amthor et al., 1996, 2002b).
This clearly indicates additional functions of Follistatin
during muscle development apart from modulating Myo-
statin activity. In fact, overexpression of Follistatin results
in an excessive muscle growth, which by far exceeds the
gain of muscle seen in the Myostatin knockout (Lee and
McPherron, 2001). This strengthens the view that Folli-
statin additionally antagonises the inhibitory effects of
other TGF-hs such as BMP-2, -4, -7 and Activin on
muscle development (Amthor et al., 2002a; Link and
Nishi, 1997). In our micromass experiments, we show that
the Follistatin blockade of Myostatin rescues the differen-
tiation of muscle. However, Follistatin on its own inhibits
muscle differentiation initially (first 24 h of micromass
culture), but eventually, the number of muscle cells is
increased (unpublished observations). This is in line with
the observation that Follistatin increases proliferation and
delays differentiation of muscle precursors, dependent
upon the presence of BMPs (Amthor et al., 2002a). Thus,
Follistatin supports muscle growth via different signalling
mechanisms, which largely depend on which TGF-h is
present. It is noteworthy that the concentration of Myo-
statin capable of halting muscle development in the micro-
mass cultures was considerably lower than that used to
soak the beads for implantation studies. In fact, concen-
trations as low as 10 ng/ml Myostatin protein inhibited
myogenesis in vitro whereas beads soaked in less than 1
mg/ml of the same protein will have little effect if at all in
vivo (Amthor et al., 2002b; Amthor, unpublished). How-
ever, the concentration of Myostatin protein in the soak
solution is not a true reflection of the concentration of
protein delivered to the limb bud. Therefore, no conclu-
sions can be drawn regarding the levels required in vivo to
mediate the effect.
The capacity of Follistatin to completely antagonise the
effect of Myostatin is in stark contrast to its interaction withBMP-7 (Amthor et al., 2002a). BMPs act dose-dependently
on muscle with high concentrations inducing muscle loss
and low concentrations promoting muscle growth (Amthor
et al., 1998). Follistatin converts the muscle growth-inhibit-
ing effect of BMP-7 into a strong stimulant of muscle
growth, which suggests that the role of Follistatin in this
case is to alter the absolute levels of BMP-7 available to
bind to its receptor (Amthor et al., 2002a). In the case of
Myostatin, Follistatin seems to completely prevent receptor
activation because Myostatin, whilst bound to Follistatin, is
unable to induce the phosphorylation of Smad3 (G. Nich-
olas, unpublished). Such differences in biological activity
can be well explained by biochemical interaction data, as the
dissociation rate of the Follistatin–BMP-7 interaction is
much higher than that of the Follistatin–Myostatin interac-
tion (1.66  103 s1 for Follistatin–BMP-7 compared to
9.52  105 s1 for Follistatin–Myostatin) (Amthor et al.,
2002a).
Although Follistatin and Myostatin can be detected in
serum, they do not form complexes. Instead, most Myosta-
tin is retained in a latent form by binding to its propeptide,
to GASP and to the protein of the Follistatin related gene
(FLRG) (Hill et al., 2002, 2003). Gene deletion has dem-
onstrated that Follistatin undoubtedly antagonises molecules
that inhibit muscle development (Matzuk et al., 1995).
Furthermore, one of the major sites of Follistatin expression
during embryogenesis is in tissues, which develop to muscle
(Amthor et al., 1996). We suggest that Follistatin acts
locally at site of production to antagonise molecules like
Myostatin. In fact, Follistatin but not FLRG harbours
heparin-binding epitopes, which facilitates interactions with
the extracellular matrix and therefore is likely to restrict
diffusion (Inouye et al., 1992; Sidis et al., 2001; Sumitomo
et al., 1995).
Recently, it was demonstrated that blockade of Myostatin
leads to a functional and histological improvement of
dystrophic muscle (Bogdanovich et al., 2002; Wagner et
al., 2002). Although our study focused on the antagonistic
effect of Follistatin on Myostatin during muscle develop-
ment, there is ample evidence that the activity of Follistatin
is not stage restricted (Lee and McPherron, 2001; Zimmers
et al., 2002). In fact, we have observed high levels of
Follistatin and Myostatin expression in dystrophic muscle
of the Dystrophin-deficient mouse (mdx mouse) (Amthor,
unpublished). Additionally, the capacity of Follistatin not
only to block Myostatin but to modulate other inhibitors of
muscle development, such as BMPs and Activin, empha-
sises that Follistatin could be a very potent molecule to
combat muscle loss during dystrophies, muscle ageing,
disuse or denervation.Acknowledgments
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